CM
Claudio Mussolino
Principal Investigator
Universitätsklinikum Freiburg
I'm working on
8 months ago
Genome and epigenome editing, cell and gene therapy
About
Claudio Mussolino develops safer precision editing platforms and multiplex gene silencing for engineered cell therapies. He holds two issued patents on HDR-enhanced Cas9 and designer epigenome modifiers, with demonstrated reductions in mutational burden in primary human cells and CAR T cells.
Partnering listings
Learn more
Universitätsklinikum Freiburg
Novel base editor fusions for safer genome editing with reduced genomic rearrangements
A genome editing platform that fuses NHEJ-inhibitory effectors to base editors, reducing unwanted double-strand breaks and genomic rearrangements while preserving precise base conversion. Deliverable via mRNA and lipid n...
TechnologyConceptualUniversity
Universitätsklinikum Freiburg
Multiplexed epigenome editing for enhanced CAR T cell potency
A novel genotoxic-free multiplexed epigenome editing strategy to enhance CAR T cell potency by inhibiting immune checkpoint receptors, improving their efficiency in tumor eradication without the risks of traditional gene...
TechnologyConceptualUniversity
No publications yet
This innovator hasn't added publications yet. In the meantime, you might want to explore their patents, funding, and other profile details.
No funding yet
This innovator hasn't added funding yet. In the meantime, you might want to explore their publications, patents, and other profile details.
Construct for epigenetic modification and its use in the silencing of genes
Issued
•2018
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
delivered to your inbox.
© 2026 Halo Cures, Inc.